Othman Leen, Koskina Lida, Huerta Nicholas, Rao Shiavax J
Department of Medicine, MedStar Union Memorial Hospital, Baltimore, MD, USA.
Division of Cardiovascular Medicine, University of Virginia, 1215 Lee St Box 800158, Charlottesville, VA, 22908, USA.
Heart Fail Rev. 2025 Mar;30(2):453-467. doi: 10.1007/s10741-024-10476-w. Epub 2024 Dec 17.
Hypertrophic cardiomyopathy (HCM) is an inherited condition characterized by left ventricular, non-dilated hypertrophy in the absence of another secondary underlying cause. There has been an ongoing increase in the diagnosis of HCM over the past couple of decades, prompting further work in the area of pharmacological and interventional therapies. This scoping review aimed to summarize the traditional therapeutic options for HCM and to explore emerging research on novel cardiac myosin inhibitors (CMIs) as a new option for pharmacologic management of HCM. A PRISMA search strategy was carried out to identify the pertinent literature on mavacamten and aficamten-two novel CMIs. Seventeen studies were included. Based on the results of the studies included in this review, cardiac myosin inhibitors have been proven to be a safe and efficacious second-line option for the management of HCM. In the foreseeable future, based on results of ongoing studies investigating patient outcomes and side-effect profile, CMIs may potentially play a larger role as part of standard treatment of HCM.
肥厚型心肌病（HCM）是一种遗传性疾病，其特征为左心室非扩张性肥厚，且不存在其他继发性潜在病因。在过去几十年中，HCM的诊断数量持续增加，这促使人们在药物和介入治疗领域开展进一步研究。本综述旨在总结HCM的传统治疗选择，并探索新型心肌肌球蛋白抑制剂（CMIs）作为HCM药物治疗新选择的新兴研究。采用PRISMA检索策略来识别有关mavacamten和aficamten这两种新型CMIs的相关文献。共纳入17项研究。基于本综述纳入研究的结果，心肌肌球蛋白抑制剂已被证明是治疗HCM的一种安全有效的二线选择。在可预见的未来，根据正在进行的研究中关于患者预后和副作用情况的结果，CMIs可能会在HCM的标准治疗中发挥更大作用。
